Search

Your search keyword '"Lopez-Pavia M"' showing total 18 results
Start Over Author "Lopez-Pavia M"
18 results on '"Lopez-Pavia M"'

1. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)

Author

Kuendgen, A., primary, Nomdedeu, M., additional, Tuechler, H., additional, Garcia-Manero, G., additional, Komrokji, R., additional, Sekeres, M., additional, Della Porta, M., additional, Cazzola, M., additional, Dezern, A., additional, Roboz, G., additional, Steensma, D., additional, Van De Loosdrecht, A., additional, Malcovati, L., additional, Schlenk, R., additional, Grau, J., additional, Calvo, X., additional, Blum, S., additional, Pereira, A., additional, Valent, P., additional, Costa, D., additional, Giagounidis, A., additional, Xicoy, B., additional, Döhner, H., additional, Platzbecker, U., additional, Pedro, C., additional, Lübbert, M., additional, Oiartzabal, I., additional, Diez-Campelo, M., additional, Cedena, M.T., additional, Machherndl-Spandl, S., additional, Lopez-Pavia, M., additional, Martinez-De-Sola, M., additional, Stauder, R., additional, Merchan, B., additional, Ganster, C., additional, Schroeder, T., additional, Voso, M.T., additional, Pfeilstöcker, M., additional, Sill, H., additional, Hildebrandt, B., additional, Esteve, J., additional, Cobo, F., additional, Solé, F., additional, Germing, U., additional, Greenberg, P., additional, Haase, D., additional, and Sanz, G., additional

Published
2023
Full Text
View/download PDF

2. P091 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)

Author

Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R., Sekeres, M., Della Porta, M., Cazzola, M., Dezern, A., Roboz, G., Steensma, D., Van De Loosdrecht, A., Malcovati, L., Schlenk, R., Grau, J., Calvo, X., Blum, S., Pereira, A., Valent, P., Costa, D., Giagounidis, A., Xicoy, B., Döhner, H., Platzbecker, U., Pedro, C., Lübbert, M., Oiartzabal, I., Diez-Campelo, M., Cedena, M.T., Machherndl-Spandl, S., Lopez-Pavia, M., Martinez-De-Sola, M., Stauder, R., Merchan, B., Ganster, C., Schroeder, T., Voso, M.T., Pfeilstöcker, M., Sill, H., Hildebrandt, B., Esteve, J., Cobo, F., Solé, F., Germing, U., Greenberg, P., Haase, D., and Sanz, G.

Published
2023
Full Text
View/download PDF

3. Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry

Author

Hernandez-Boluda J, Martinez-Cuadron D, Pereira A, Rodriguez-Veiga R, Boluda B, Gil C, Casal-Marini S, Serrano J, Martinez-Lopez J, Bergua J, Algarra L, Bernal T, Lopez-Lorenzo J, Colorado M, Lopez A, Tormo M, Sayas M, Trigo F, Lopez-Pavia M, Perez-Simon J, Lavilla-Rubira E, Rodriguez-Medina C, Rodriguez-Gutierrez J, Sanz-Caballer M, Montesinos P, and PETHEMA group

Subjects
Cancer Research, Acute leukemia, Survival, Hematopoietic Stem Cell Transplantation, Myeloproliferative neoplasm, Hematology, Myelodysplastic-Myeloproliferative Diseases, Acute leukemia, Myelodysplastic/myeloproliferative neoplasm, Myeloproliferative neoplasm, Survival, Treatment, Treatment, Leukemia, Myeloid, Acute, Oncology, Myelodysplastic Syndromes, Myelodysplastic/myeloproliferative neoplasm, Humans, Registries
Abstract

PETHEMA group., Treatment of acute myeloid leukemia (AML) evolving from myeloproliferative (MPN) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) is challenging. We evaluated disease characteristics, treatment patterns and outcomes in 372 patients diagnosed with AML after MPN or MDS/MPN over a 27-year period. Frontline treatment was intensive chemotherapy (38%), hypomethylating agents [HMAs] (17%), non-intensive chemotherapy (14%), and supportive care (31%). Median overall survival was 4.8 months, with a 5-year survival rate of 4%. Median survival was 2.8, 3.9 and 8.3 months for the 1992-2010, 2011-2015 and 2016-2019 periods, respectively (test for trend p

Published
2022

4. O29 - Topic: AS02-Epidemiology: COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)

Author

Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R., Sekeres, M., Della Porta, M., Cazzola, M., Malcovati, L., Dezern, A., Roboz, G., Steensma, D., Haase, D., Stauder, R., Cedena, M.T., Van De Loosdrecht, A., Schlenk, R., Blum, S., Grau, J., Calvo, X., Valent, P., Costa, D., Pereira, A., Xicoy, B., Döhner, H., Platzbecker, U., Giagounidis, A., Pedro, C., Lübbert, M., Oiartzabal, I., Díez-Campelo, M., Machherndl-Spandl, S., Lopez-Pavia, M., Martinez-De-Sola, M., Merchan, B., Ganster, C., Schroeder, T., Voso, M.T., Hildebrandt, B., Esteve, J., Nomdedeu, B., Cobo, F., Haas, R., Sole, F., Germing, U., Greenberg, P., Sill, H., Pfeilstöcker, M., and Sanz, G.

Published
2021
Full Text
View/download PDF

5. Topic: AS02-Epidemiology

Author

Kuendgen, A., primary, Nomdedeu, M., additional, Tuechler, H., additional, Garcia-Manero, G., additional, Komrokji, R., additional, Sekeres, M., additional, Della Porta, M., additional, Cazzola, M., additional, Malcovati, L., additional, Dezern, A., additional, Roboz, G., additional, Steensma, D., additional, Haase, D., additional, Stauder, R., additional, Cedena, M.T., additional, Van De Loosdrecht, A., additional, Schlenk, R., additional, Blum, S., additional, Grau, J., additional, Calvo, X., additional, Valent, P., additional, Costa, D., additional, Pereira, A., additional, Xicoy, B., additional, Döhner, H., additional, Platzbecker, U., additional, Giagounidis, A., additional, Pedro, C., additional, Lübbert, M., additional, Oiartzabal, I., additional, Díez-Campelo, M., additional, Machherndl-Spandl, S., additional, Lopez-Pavia, M., additional, Martinez-De-Sola, M., additional, Merchan, B., additional, Ganster, C., additional, Schroeder, T., additional, Voso, M.T., additional, Hildebrandt, B., additional, Esteve, J., additional, Nomdedeu, B., additional, Cobo, F., additional, Haas, R., additional, Sole, F., additional, Germing, U., additional, Greenberg, P., additional, Sill, H., additional, Pfeilstöcker, M., additional, and Sanz, G., additional

Published
2021
Full Text
View/download PDF

6. Evolving treatment patterns and outcomes in older patients (>= 60 years) with AML: changing everything to change nothing?

Author

Martinez-Cuadron D, Serrano J, Gil C, Tormo M, Martinez-Sanchez P, Perez-Simon J, Garcia-Boyero R, Rodriguez-Medina C, Lopez-Pavia M, Benavente C, Bergua J, Lavilla-Rubira E, Amigo M, Herrera P, Alonso-Dominguez J, Bernal T, Colorado M, Sayas M, Algarra L, Vidriales M, Rodriguez-Macias G, Vives S, Perez-Encinas M, Lopez A, Noriega V, Garcia-Fortes M, Ramos F, Rodriguez-Gutierrez J, Costilla-Barriga L, Labrador J, Boluda B, Rodriguez-Veiga R, Martinez-Lopez J, Sanz M, and Montesinos P

Abstract

There are no studies analyzing how therapeutic changes impact on outcomes of older AML patients. This study analyzes patient ' s and disease characteristics, treatment patterns, and outcomes of 3637 AML patients aged >= 60 years reported to the PETHEMA registry. Study periods were 1999-2006 (before hypomethylating agents-HMAs availability) vs 2007-2013, and treatments were intensive chemotherapy (IC), non-intensive, clinical trial (CT), and supportive care only (SC). Median age was 72 (range, 60-99), 57% male, median ECOG 1 (range, 0-4), secondary AML 914 (30%), with adverse-risk genetic in 720 (32%). Treatment differed between study periods (1999-2006 vs 2007-2013): IC 58% vs 32%, non-intensive 1 vs 23%, CT 0 vs 2%, SC 27 vs 28% (p < 0.001). Median OS was 4.7 months (1-year OS 29% and 5-years 7%, without differences between periods), 1.2 for SC, 7.8 for non-intensive, 8.6 for IC, and 10.4 for CT (p < 0.001). OS improved in the 2007-2013 period for IC patients (10.3 vs 7.5 months,p = 0.004), but worsened for SC patients (1.2 vs 1.6 months,p = 0.03). Our real-life study shows that, despite evolving treatment for elderly patients during the last decade, OS has remained unchanged. Epidemiologic registries will critically assess whether novel therapies lead to noteworthy advances in the near future (#NCT02606825).

Published
2021

7. STUDY OF THE INTERACTOME OF ACUTE MYELOID LEUKEMIA

Author

Ibanez, M., Carbonell-Caballero, J., Garcia-Alonso, L., Such, E., Barragan, E., Lopez-Pavia, M., Llop, M., Alonso, C., Montesinos, P., Sanz, M. A., and Joaquin Cervera, Dopazo J.

Published
2015

10. 211 SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY: THE LARGEST RETROSPECTIVE STUDY OF ESAS FOR THE TREATMENT OF ANEMIA IN LOWER RISK MDS PATIENTS

Author

Campelo, M. Diez, primary, Lorenzo, J.I., additional, Benlloch, L., additional, Lopez-Pavia, M., additional, Such, E., additional, Bernal, T., additional, Luño, E., additional, Davila, J., additional, Ramos, F., additional, Calabuig, M., additional, Pomares, H., additional, Gonzalez, B., additional, Merchan, B., additional, Barranco, E., additional, Tello, R. Sancho, additional, Callejas, M., additional, Requena, M.J., additional, Jimenez, M.J., additional, Pedreño, M., additional, Vicente, A.I., additional, Medina, A., additional, Campeny, A., additional, Sansa, M. Cortes, additional, Pedro, C., additional, Falantes, J.F., additional, Arilla, M.J., additional, Barez, A., additional, Garcia, R., additional, Arcos, M.J., additional, Gomez, V., additional, Muñoz, C., additional, Cervero, C., additional, Casaño, J., additional, de Paz, R., additional, Amigo, L., additional, Insunza, A., additional, Muñoz, J.A., additional, Cedena, M.T., additional, Gomez, M., additional, Font, P., additional, del Campo, R., additional, Lago, C. Fernandez, additional, Hurtado, J.A. Gonzalez, additional, Latorre, M.D. Linares, additional, Casado, A. Mora, additional, Vahi, M., additional, Sanz, G.F., additional, and Cañizo, M.C., additional

Published
2015
Full Text
View/download PDF

12. STUDY OF PRE-EXISTING MUTATIONS IN HEMATOPOYETIC CELLS OF THE BONE MEDULA IN PATIENTS WITH MYELOID NEOPLASIAS RELATED TO THERAPY

Author

Ibanez, M., Lopez Pavia, M., Such, E., Navarro, B., Neef, A., Boluda Navarro, M., Llop, M., Sargas, C., Matteo, D. M., Liquori, A., Gonzalez Romero, E., Company, D., Jerez, A., Varcarcel, D., Montoro, J., Diez Campelo, M., Hernandez Rivas, J. M., Hernandez Sanchez, J. M., Teresa Bernal, San Juan Pla, A., Montesinos, P., Barragan, E., Sanz, M. A., Cervera, J., and Sanz, G.

13. COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)

Author

Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R., Sekeres, M., Della Porta, M., Cazzola, M., LUCA MALCOVATI, Dezern, A., Roboz, G., Steensma, D., Haase, D., Stauder, R., Cedena, M. T., Loosdrecht, A., Schlenk, R., Blum, S., Grau, J., Calvo, X., Valent, P., Costa, D., Pereira, A., Xicoy, B., Doehner, H., Platzbecker, U., Giagounidis, A., Pedro, C., Luebbert, M., Oiartzabal, I., Diez-Campelo, M., Machherndl-Spandl, S., Lopez-Pavia, M., Martinez-De-Sola, M., Merchan, B., Ganster, C., Schroeder, T., Voso, M. T., Hildebrandt, B., Esteve, J., Nomdedeu, B., Cobo, F., Haas, R., Sole, F., Germing, U., Greenberg, P., Sill, H., Pfeilstoecker, M., and Sanz, G.

16. SPRESAS (SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY) SUBANALYSIS: IMPACT OF COMORBIDITIES AND CENTER LEVEL ON RESPONSE TO ESAS IN LOWER RISK MDS

Author

Davila Valls, J., Sanchez Barba, M., Lopez Pavia, M., Such, E., Teresa Bernal, Luno, E., Ramos, F., Calabuig, M., Pomares, H., Gonzalez, B., Merchan, B., Barranco, E., Sancho Tello, R., Callejas, M., Requena, M. J., Jimenez, M. J., Pedreno, M., Medina, A., Vicente, A. I., Campeny, A., Cortes Sansa, M., Pedro, C., Falantes, J. F., Arilla, M. J., Barez, A., Garcia, R., Arcos, M. J., Gomez, V., Munoz, C., Cervero, C., Casano, J., Paz, R., Amigo, L., Insunza, A., Munoz, J. A., Cedena, M. T., Gomez, M., Font, P., Del Campo, R., Fernandez Lago, C., Gonzalez Hurtado, J. A., Linares Latorre, M. D., Mora Casado, A., Vahi, M., Benlloch, L., Sanz, G. F., Del Canizo Fernandez-Roldan, M. C., and Diez Campelo, M.

17. SPRESAS (SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY): THE LARGEST RETROSPECTIVE STUDY OF TREATMENT WITH ESAS IN LOWER RISK MDS

Author

Diez Campelo, M., Lorenzo, J. I., Benlloch, L. I., Davila, J., Teresa Bernal, Luno, E., Lopez-Pavia, M., Such, E., Ramos, F., Calabuig, M., Pomares, H., Gonzalez, B., Merchan, B., Barranco, E., Sancho Tello, R., Callejas, M., Requena, M. J., Jimenez, M. J., Pedreno, M., Vicente, A. I., Medina, A., Campeny, A., Cortes Sansa, M., Pedro, C., Falantes, J. F., Arilla, M. J., Barez, A., Garcia, R., Arcos, M. J., Gomez, V., Munoz, C., Cervero, C., Casano, J., Paz, R., Amigo, M. L., Insunza, A., Munoz, J. A., Cedena, M. T., Gomez, M., Font, P., Del Campo, R., Fernandez Lago, C., Gonzalez Hurtado, J. A., Linares Latorre, M. D., Mora Casado, A., Vahi, M., Sanz, G., and Del Canizo, C.

18. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.

Author

Elena C, Gallì A, Such E, Meggendorfer M, Germing U, Rizzo E, Cervera J, Molteni E, Fasan A, Schuler E, Ambaglio I, Lopez-Pavia M, Zibellini S, Kuendgen A, Travaglino E, Sancho-Tello R, Catricalà S, Vicente AI, Haferlach T, Haferlach C, Sanz GF, Malcovati L, and Cazzola M

Subjects
Adult, Aged, Aged, 80 and over, Clinical Decision-Making, Cohort Studies, Female, Follow-Up Studies, Humans, Leukemia, Myelomonocytic, Chronic pathology, Male, Middle Aged, Neoplasm Grading, Phenotype, Prognosis, Risk Factors, Survival Rate, Young Adult, Biomarkers, Tumor genetics, Chromosome Aberrations, Leukemia, Myelomonocytic, Chronic genetics, Mutation genetics, Risk Assessment methods
Abstract

Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative neoplasm with variable clinical course. To predict the clinical outcome, we previously developed a CMML-specific prognostic scoring system (CPSS) based on clinical parameters and cytogenetics. In this work, we tested the hypothesis that accounting for gene mutations would further improve risk stratification of CMML patients. We therefore sequenced 38 genes to explore the role of somatic mutations in disease phenotype and clinical outcome. Overall, 199 of 214 (93%) CMML patients carried at least 1 somatic mutation. Stepwise linear regression models showed that these mutations accounted for 15% to 24% of variability of clinical phenotype. Based on multivariable Cox regression analyses, cytogenetic abnormalities and mutations in RUNX1, NRAS, SETBP1, and ASXL1 were independently associated with overall survival (OS). Using these parameters, we defined a genetic score that identified 4 categories with significantly different OS and cumulative incidence of leukemic evolution. In multivariable analyses, genetic score, red blood cell transfusion dependency, white blood cell count, and marrow blasts retained independent prognostic value. These parameters were included into a clinical/molecular CPSS (CPSS-Mol) model that identified 4 risk groups with markedly different median OS (from >144 to 18 months, hazard ratio [HR] = 2.69) and cumulative incidence of leukemic evolution (from 0% to 48% at 4 years, HR = 3.84) (P < .001). The CPSS-Mol fully retained its ability to risk stratify in an independent validation cohort of 260 CMML patients. In conclusion, integrating conventional parameters and gene mutations significantly improves risk stratification of CMML patients, providing a robust basis for clinical decision-making and a reliable tool for clinical trials., (© 2016 by The American Society of Hematology.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results